Codex Labs has announced the launch of the first product in a new collection, KĀNGFÙ, that is focused on healing damaged skin ...

In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

TREMFYA ® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children ...

The skin on different areas of the body requires different regimens. Here’s how dermatologists recommend treating it on your ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

Topicals are often the first-line treatment for psoriasis, but as the condition progresses, you may need to consider systemic treatments to manage your symptoms. Here’s what to know about your options ...

Oct 14th, 2025 - Codex Labs, a Silicon Valley skintech company, has launched KĀNGFÙ Cooling Recovery Gel, a game-changing ...

People increasingly turn to do-it-yourself healthcare amid long waits for medical appointments and a rise in self-care ...

Princeton, New Jersey Friday, September 26, 2025, 16:00 Hrs [IST] ...

United States: Projected CAGR of 5.1%, with market value rising from USD 127.3 billion in 2025 to USD 209.4 billion by 2035, ...

Psoriasis, meanwhile, is an autoimmune condition in which the immune system attacks the body's own tissues, namely skin cells. People usually have flareups of the condition, which are treated with ...